BioLineRx Finalizes $3.75M Offering Terms, Amends Armistice Warrants
BLRX sits 25% above its 52-week low of $2.15 on elevated volume (9.1× avg).
Summary
BioLineRx filed definitive agreements for its $3.75M registered direct offering, revealing a warrant amendment with Armistice Capital and 8% placement agent fees. The raise follows a going concern warning with only $13.1M in cash.
Key Events · Financing and Capital Events · BLRX
-
Offering Terms Finalized
Definitive agreements filed for $3.75M registered direct offering: 480,696 ADSs at $2.78 plus pre-funded warrants for 868,225 ADSs at $2.7799, with ordinary warrants for 2,023,382 ADSs at $2.78 exercise price.
-
Armistice Warrant Amendment
Existing warrants for 277,273 ADSs held by Armistice Capital Master Fund were amended to reduce exercise price to $2.78 and extend term to August 31, 2031 — a concession increasing potential dilution.
-
Placement Agent Fees
Chardan Capital Markets receives 7.0% cash fee plus 1.0% management fee on gross proceeds, plus up to $50,000 in accountable expenses — total compensation of approximately 8% plus expenses.
-
Going Concern Context
This raise follows BioLineRx's August 31 6-K flagging going concern uncertainty with only $13.1 million in cash, making the $3.75M proceeds critical for near-term operations.
Analysis · BLRX · Life Sciences
The definitive agreements for BioLineRx's $3.75 million registered direct offering have been filed, adding material terms not in the August 28 pricing announcement. Existing warrants held by Armistice Capital Master Fund were amended to reduce the exercise price to $2.78 and extend the term to 2031 — a concession that increases potential future dilution. Placement agent compensation totals 8% in cash fees plus up to $50,000 in expenses. The offering comes just days after BioLineRx flagged going concern uncertainty with only $13.1 million in cash, making this capital raise critical for near-term runway.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLRX was trading at $2.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $2.15 to $4.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.